ライフサイエンスコーパス: POTS

1 POTS and NCS differ in tonic cardiac sympathetic functio

2 POTS care was driven by individual human agency and inte

3 POTS is a common and therapeutically challenging conditi

4 POTS is associated with lower GH levels.

5 POTS may be associated with increased limb blood flow ("

6 POTS patients had significantly higher composite OHQ sco

7 POTS phenotypes are not distinguishable based on symptom

8 A total of 14 POTS patients and 13 healthy control subjects (HC), age

9 s were found: 1) A challenging condition, 2) POTS healthcare provision - services by accident not des

10 d 12 healthy controls, 9 IST, 30 VVS, and 30 POTS patients (13-23years) selected randomly by disorder

11 ased: HR(transition)=115+/-6 (IST), 123+/-8 (POTS), 124+/-7 (VVS), P=ns.

12 oneal muscle sympathetic nerve activity in 9 POTS patients and 9 control subjects at rest and during

13 ed responses to specific treatments, e.g., a POTS-dominant cluster benefiting from autonomic modulato

14 no differences in symptom presentation among POTS phenotypes.

15 with female control subjects (p < 0.05) and POTS patients (p < 0.001).

16 tudy addressed whether patients with COI and POTS or NCS have neurocirculatory abnormalities during s

17 Volume-pressure relations of controls and POTS patients with normal P(v) and high P(v) were not di

18 holds that reveal that the BR of healthy and POTS groups present significantly different maximum CCF

19 tolic and mean arterial pressures in IST and POTS were higher versus controls.

20 ic and asymptomatic groups within the OH and POTS groups.

21 Because POTS and NCS both include specific abnormalities of card

22 d presents with overlapping symptoms between POTS and non-POTS patients.

23 Disorder Treatment Study for Young Children [POTS Jr]) conducted at 3 academic medical centers betwee

24 her research is needed in better classifying POTS phenotypes with the potential goal of tailoring tre

25 Long COVID POTS confers lower physical activity and capacity compar

26 er women with highly symptomatic long COVID, POTS is common and presents with overlapping symptoms be

27 ic intolerance on HUTT, with 4 demonstrating POTS, 15 provoked orthostatic intolerance (POI) after ni

28 f clinical recovery than those demonstrating POTS.

29 (MSN) discharge characteristics in 12 female POTS patients and in 9 male and 12 female control subjec

30 A subgroup of low-flow POTS patients had exaggerated venoconstriction to phenyl

31 ) combined with iontophoresis in 15 low-flow POTS patients, 17 normal-flow POTS patients, and 13 heal

32 rn of thermal hyperemia response in low-flow POTS subjects during saline administration resembled the

33 which was insensitive to L-NAME in low-flow POTS subjects.

34 ycardia syndrome (POTS), designated low-flow POTS, is associated with decreased peripheral blood flow

35 eous vasoregulation was similar for low-flow POTS, normal-flow POTS, and reference subjects.

36 decreased peripheral blood flow in low-flow POTS, we performed experiments using laser-Doppler flowm

37 nitric oxide release is reduced in low-flow POTS.

38 in 15 low-flow POTS patients, 17 normal-flow POTS patients, and 13 healthy reference volunteers varyi

39 n was similar for low-flow POTS, normal-flow POTS, and reference subjects.

40 ated compression garments as a treatment for POTS using a head-up tilt test (HUT), and a noninflatabl

41 ction were analyzed in skin fibroblasts from POTS and compared with control cells.

42 agnosed with POTS, 128 (27%) did not fulfill POTS criteria, while 196 (42%) had no clinical signs of

43 Adult patients referred for COI who had POTS (n=90, mean+/-SEM age 40+/-1 years, 86% women) or N

44 In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized,

45 ate and QOL in patients with hyperadrenergic POTS as the predominant subtype.

46 (NE) levels in patients with hyperadrenergic POTS defined by plasma NE >600 pg/ml and abnormal tilt t

47 In POTS patients, high dietary sodium intake compared with

48 In POTS, the HS diet reduced upright heart rate and heart r

49 relation changes in BR and CA using ACCF in POTS for early clinical detection and diagnosis.

50 stent with increased sympathetic activity in POTS and did not change in response to hypotension.

51 ion to the increase in total MSN activity in POTS patients compared with female control subjects, and

52 Mean age in POTS was 30 +/- 9.8 years (84.6% women) versus controls

53 tion was shifted toward larger amplitudes in POTS patients (p < 0.005), consistent with increased sym

54 for establishing the role of autoimmunity in POTS.

55 d to OHDAS in POTS and supine systolic BP in POTS and controls, but not heart rate neither group.

56 ency result in normal or even elevated BP in POTS patients.

57 ts (p < 0.001), whereas it did not change in POTS patients.

58 Venous compliance in POTS is similar to that in control subjects.

59 results from increased venous compliance in POTS patients.

60 (Hemodynamic Effects of Compression in POTS; NCT03484273).

61 rate compared with a low sodium (LS) diet in POTS patients, and secondarily its effect on plasma volu

62 Supine Pv was not different in POTS, but upright leg Pv tended to be increased above co

63 L, heart rate, and mitochondrial function in POTS patients.

64 e activities is inversely related with GH in POTS.

65 o the total activity increase was greater in POTS patients than in female (p < 0.05) and male (p < 0.

66 es orthostatic tolerance and hemodynamics in POTS.

67 and heart rate were significantly higher in POTS patients than in controls.

68 nd upright norepinephrine remained higher in POTS than in HC on the HS diet (median 117 beats/min [in

69 ot systolic BP, were significantly higher in POTS.

70 A lower SV resulted in a higher HR in POTS at any given oxygen uptake (V(O(2))) during exercis

71 Autonomic function was intact in POTS patients.

72 BP is inversely associated with GH levels in POTS and healthy individuals.

73 plasma GH levels were significantly lower in POTS (0.53 ng/mL) than controls (2.33 ng/mL, p = 0.04).

74 and mRNA expression were 2-3 times lower in POTS fibroblasts, and choline uptake was reduced 60% (P

75 V(O(2peak)) was lower in POTS than controls (26.1 +/- 1.0 (SEM) vs. 36.3 +/- 0.9

76 l [interquartile range: 498 to 919 pg/ml] in POTS vs. 85 beats/min [interquartile range: 77 to 95 bea

77 ed sympathetic outflow significantly more in POTS patients than in controls despite a similar BP decr

78 Upright HR increased most in POTS then IST and VVS, with diverse changes in CO, SVR,

79 ting diastolic function was mostly normal in POTS before training, though diastolic suction was impai

80 ulatory control during exercise is normal in POTS; and (b) that physical 'reconditioning' with exerci

81 GH levels were inversely related to OHDAS in POTS and supine systolic BP in POTS and controls, but no

82 The findings suggest that pooling in POTS is due to blunted arterial vasoconstriction, which

83 ents between BR and CA indicated positive in POTS groups and negative in the healthy group.

84 fied 30 differentially expressed proteins in POTS compared with healthy controls.

85 oteomic pathways differentially regulated in POTS.

86 At rest, the burst frequency was similar in POTS patients and controls (18.1+/-6.2 and 20.1+/-7.9 bu

87 Mean cardiac norepinephrine spillover in POTS (171+/-30 pmol/min, N=16) was higher and in NCS (62

88 ociated with a reduced stroke volume (SV) in POTS, and that the high heart rate (HR) observed at rest

89 enuated tachycardia and improved symptoms in POTS.

90 ay contribute to the relative tachycardia in POTS.

91 tion significantly attenuated tachycardia in POTS.

92 neural activity and orthostatic tolerance in POTS women.

93 After training in POTS, HR became lower at any given due to increased SV w

94 lates blood pressure and vasoconstriction in POTS women during orthostatic stress.

95 lates blood pressure and vasoconstriction in POTS women during tilting.

96 Notable improvements include POTS symptom severity (p < 0.0001), physical functioning

97 dividuals (case-control ratio 1:1) including POTS and healthy controls.

98 on-severe group, AAPI patients had increased POTS/dysautonomia and respiratory symptoms, and NHB pati

99 and equivalently reduces upright CO, in IST, POTS, and VVS.

100 proved QOL metrics, as assessed by the Malmo POTS Symptom Score Survey (MAPS) and the General Health

101 Ten of 19 patients no longer met POTS criteria after training, whereas patient quality of

102 th overlapping symptoms between POTS and non-POTS patients.

103 ical activity and capacity compared with non-POTS long COVID and should be systematically assessed in

104 as to determine plasma protein biomarkers of POTS and to reveal proteomic pathways differentially reg

105 a conceptual framework of the experience of POTS conceptualised through a critical realist lens.

106 Research into the experience of POTS is emerging, with no currently published studies in

107 his study aimed to understand experiences of POTS, its challenges, and aspects of care from the persp

108 tification reveal the proteomic footprint of POTS in terms of a hypercoagulable state, proinflammator

109 assess the prevalence and clinical impact of POTS in a series of well-characterized patients with lon

110 The underlying pathophysiology of POTS is not fully understood, but it has been suggested

111 ay play a key role in the pathophysiology of POTS.

112 study describes the symptom presentation of POTS by phenotypes at a subspecialty POTS clinic.

113 predisposition to and greater prevalence of POTS in female individuals.

114 requirement for a system wide recognition of POTS to move the landscape away from one of individual r

115 ia, while 196 (42%) had no clinical signs of POTS.

116 ial diagnoses, evaluations, and treatment of POTS from cardiological and neurological perspectives.

117 Much of the current understanding of POTS is based on clinical expertise, particularly regard

118 It seems reasonable to offer POTS a new name based on its underlying pathophysiology,

119 Overall, POTS features increased heart rate and sympathetic nervo

120 n clinical expertise, particularly regarding POTS phenotypes and their potential role in targeting ph

121 Twenty-seven POTS patients underwent autonomic function tests, cardia

122 tion of POTS by phenotypes at a subspecialty POTS clinic.

123 and Test for those with clinically suspected POTS.

124 OI) occurs in postural tachycardia syndrome (POTS) and in some individuals with repeated neurocardiog

125 In postural tachycardia syndrome (POTS) and repeated neurocardiogenic presyncope (NCS), or

126 e postural orthostatic tachycardia syndrome (POTS) and that exercise training improves this syndrome.

127 e postural orthostatic tachycardia syndrome (POTS) and the health professionals who care for them: a

128 e postural orthostatic tachycardia syndrome (POTS) are primarily premenopausal women, which may be at

129 Patients with postural tachycardia syndrome (POTS) experience considerable disability, but in most, t

130 f postural orthostatic tachycardia syndrome (POTS) in long COVID has been a growing concern since the

131 Postural tachycardia syndrome (POTS) induces disabling chronic orthostatic intolerance

132 Postural tachycardia syndrome (POTS) induces disabling chronic orthostatic intolerance

133 Postural orthostatic tachycardia syndrome (POTS) is a cardiovascular autonomic disorder characteriz

134 Postural orthostatic tachycardia syndrome (POTS) is a cardiovascular autonomic disorder with poorly

135 Postural orthostatic tachycardia syndrome (POTS) is a chronic form of orthostatic intolerance assoc

136 Postural orthostatic tachycardia syndrome (POTS) is a complex, multifaceted disorder that impairs f

137 Postural orthostatic tachycardia syndrome (POTS) is a disorder of orthostatic intolerance that prim

138 Postural orthostatic tachycardia syndrome (POTS) is an under recognised, predominantly female condi

139 Postural orthostatic tachycardia syndrome (POTS) is characterized by an abnormal increase in heart

140 Postural tachycardia syndrome (POTS) is characterized by excessive orthostatic tachycar

141 Postural tachycardia syndrome (POTS) is related to defective peripheral vasoconstrictio

142 Postural orthostatic tachycardia syndrome (POTS) presents excessive orthostatic tachycardia and ort

143 Postural orthostatic tachycardia syndrome (POTS) presents heterogeneously and is diagnosed when app

144 e postural orthostatic tachycardia syndrome (POTS) report fluctuations in orthostatic tolerance throu

145 treatment of postural tachycardia syndrome (POTS) to counteract the hypovolemia and elevated plasma

146 k postural orthostatic tachycardia syndrome (POTS) to PASC.

147 racterized by postural tachycardia syndrome (POTS) with exaggerated tachycardia, orthostatic symptoms

148 cardia (IST), postural tachycardia syndrome (POTS), and vasovagal syncope (VVS), symptomatic excessiv

149 ne variant of postural tachycardia syndrome (POTS), designated low-flow POTS, is associated with decr

150 tension (OH), postural tachycardia syndrome (POTS), or normal HUT groups.

151 e postural orthostatic tachycardia syndrome (POTS), similar to physical deconditioning.

152 Postural orthostatic tachycardia syndrome (POTS), the most common form of orthostatic intolerance i

153 h postural orthostatic tachycardia syndrome (POTS), who presented with low plasma choline and betaine

154 ents with the postural tachycardia syndrome (POTS).

155 olerance with postural tachycardia syndrome (POTS).

156 Ten POTS women were studied during the early follicular (EF)

157 These findings support the hypothesis that POTS may be an autoimmune, inflammatory and hyperadrener

158 The POTS group also had higher mean arterial norepinephrine

159 The POTS group had a relatively fast mean heart rate (79+/-2

160 The POTS group was divided into patients with high venous pr

161 e walk test were significantly higher in the POTS group, both during walking and at rest afterward, w

162 ex was mildly weak, it did not differ in the POTS group.

163 changes significantly into phase lag in the POTS group.

164 The characteristics of the POTS fibroblasts described here represent a first model

165 earm vascular resistance (52+/-6 U) than the POTS group (36+/-2 U, P=0.003).

166 Thus, POTS only affects BR.

167 When POTS cells were treated with choline, transporter was up

168 ession has not been evaluated in adults with POTS.

169 udied 12 patients 13 to 19 years of age with POTS and defective leg vasoconstriction and 13 age-match

170 ng of sympathetic fiber loss associated with POTS, may contribute to the predisposition to and greate

171 s many disease entities can be confused with POTS, it becomes critical to identify this syndrome.

172 ssment outcomes between those diagnosed with POTS and the remaining long COVID patients.

173 OVID patients, 143 (31%) were diagnosed with POTS, 128 (27%) did not fulfill POTS criteria, while 196

174 tochondrial function in 20 participants with POTS (>= 30 bpm increase in upright heart rate) and a ba

175 ow level of aldosterone in the patients with POTS (190+/-140 pmol/L versus 380+/-230 pmol/L; P=0.017)

176 Sera were collected from 116 patients with POTS (91% female; medium age, 29 years) and 81 healthy c

177 The majority of patients with POTS (98.3%) and all controls (100%) had alpha1 adrenerg

178 -matched case-control study in patients with POTS (age 31 9 years; n = 42) and healthy controls (32 9

179 g/kg per minute) for 1 hour in patients with POTS (n=15) and healthy controls (n=13) in the supine po

180 Patients with POTS (n=15) and healthy controls (n=14) underwent invest

181 METHODS AND In protocol 1, patients with POTS (n=54) underwent acute drug trials of propranolol 2

182 gic antagonist, esmolol, in 14 patients with POTS aged 13 to 19 years.

183 odium excretion was similar in patients with POTS and controls (-49+/-12 versus -60+/-16 mEq/g creati

184 Ages were similar for patients with POTS and controls (mean+/-SEM, 30+/-2 versus 26+/-1 year

185 bility to discriminate between patients with POTS and controls.

186 Patients with POTS and healthy controls do not differ in their enzyme-

187 tein-coupled receptors between patients with POTS and healthy controls.

188 ely tested the hypothesis that patients with POTS are hypovolemic compared with healthy controls and

189 re asymptomatic during HUT and patients with POTS are more likely to be symptomatic than patients wit

190 ly increased in the forearm in patients with POTS but was increased in the calf (9.3+/-2.2 versus 5.7

191 upine and upright positions in patients with POTS compared with control subjects (P=0.01, upright leg

192 ine was significantly lower in patients with POTS compared with controls (10.1+/-1.2 versus 16.8+/-1.

193 esponses to Ang II infusion in patients with POTS compared with healthy controls.

194 n response to Ang II infusion, patients with POTS had a blunted increase compared with controls in me

195 Patients with POTS had a greater deficit in plasma volume (334+/-187 v

196 Patients with POTS had a higher orthostatic increase in HR than contro

197 Patients with POTS had symptoms more frequently than patients with OH

198 Patients with POTS have blunted vasopressor response to Ang II and imp

199 We have previously found that patients with POTS have increases in plasma angiotensin II (Ang II) th

200 Patients with POTS have marked increases in heart rate during orthosta

201 Patients with POTS have paradoxically unchanged plasma renin activity

202 Patients with POTS or NCS underwent measurements of neurochemical indi

203 Seventeen patients with POTS underwent acute drug trials of pyridostigmine 30 mg

204 In protocol 2, 18 patients with POTS underwent similar trials of high-dose (80 mg) versu

205 ilarly with Ang II infusion in patients with POTS versus controls (-166+/-20 versus -181+/-17 mL/min

206 The proportion of patients with POTS versus healthy controls who fell above the diagnost

207 Patients with POTS were younger (mean age, 40.0 versus 44.0 versus 47.

208 s for enhanced leg swelling in patients with POTS with increased arterial blood flow.

209 ite the lower plasma volume in patients with POTS, there was not a compensatory increase in plasma re

210 d symptoms during HUT in adult patients with POTS.

211 different between controls and patients with POTS.

212 (GH), we studied GH levels in patients with POTS.

213 r responses during exercise in patients with POTS.

214 proves exercise performance in patients with POTS.

215 and improve symptom burden in patients with POTS.

216 and improve symptom burden in patients with POTS.

217 r participants were included, 19 people with POTS and 25 health professionals.

218 ualitative study to explore both people with POTS and health professional experiences of looking afte

219 d: 1) a need for empowering both people with POTS and health professionals through shared care and de

220 Understanding the experiences of people with POTS and the health professionals who see them.

221 People with POTS took individual responsibility for their self-manag

222 Compared with those with POTS, patients with POI described significantly earlier

223 rol across the menstrual cycle in women with POTS are unknown.

224 nce across the menstrual cycle in women with POTS.

225 nce across the menstrual cycle in women with POTS.

226 ardiogenic syncope/presyncope (NCS), without POTS.

227 Nineteen (18 women) POTS patients completed a 3 month training programme.